Bookmark and Share
Carmustine (CID 2578) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(103)
 
 
Inactive(1013)
 
 
Inconclusive(91)
 
 
Unspecified(268)
 
 
Top Targets:
7TM GPCR Srx(43)
 
 
 
7TM GPCR Srsx(33)
 
 
 
p450(27)
 
 
 
 
NR LBD PPAR(13)
 
 
 
NR LBD ER(12)
 
 
 
 
BioAssay Types:
Confirmatory(582)
 
 
 
 
 
Screening(327)
 
 
Literature(248)
 
 
 
 
 
Summary(25)
 
 
 
 
BioActivity Types:
Potency(488)
 
 
 
 
 
IC50(177)
 
 
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 1235    Data Row: 1475   Total Pages: 30   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID144203648]
Potency-Replicate_1 1.1883qHTS assay for small molecule agonists of the p53 signaling pathway [AID651631, Type: confirmatory]Cellular tumor antigen p53 [gi:269849759]
View
2
[SID103173718]
IC50 1.42In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr [AID248624, Type: Literature]
View
3
[SID103173718]
IC50 2.37In vitro inhibitory concentration against growth of SNB19 glioblastoma cell line in clonogenic survival assay after 24 hr [AID248623, Type: Literature]
View
4
[SID26747453]
Potency 3.1623qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) [AID1030, Type: confirmatory]aldehyde dehydrogenase 1 family, member A1 [Homo sapiens] [gi:30582681]
View
5
[SID103173718]
ED50 4Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice. [AID97975, Type: Literature]
View
6
[SID103173718]
ED50 4In vitro inhibitory activity against murine leukemia L1210 cells [AID97982, Type: Literature]
View
7
[SID103173718]
IC50 4.5Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia [AID96470, Type: Literature]
View
8
[SID103173718]
IC50 4.5Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay [AID103374, Type: Literature]
View
9
[SID103173718]
IC50 5Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay [AID80645, Type: Literature]
View
10
[SID103173718]
IC50 5.9Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia [AID154140, Type: Literature]
View
11
[SID103173718]
ED50 6.3Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree [AID152565, Type: Literature]
View
12
[SID103173718]
IC50 7Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytototoxicity Assay [AID100996, Type: Literature]
View
13
[SID103173718]
IC50 7.4Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma [AID101660, Type: Literature]
View
14
[SID170464880]
Ratio Potency (uM) 7.49722qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary [AID743219, Type: summary]nuclear factor erythroid 2-related factor 2 isoform 1 [Homo sapiens] [gi:20149576]
View
15
[SID103173718]
IC50 8Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay [AID7875, Type: Literature]
View
16
[SID103173718]
IC50 8.2Dose required to inhibit cell growth was determined against CHO cell line [AID47684, Type: Literature]
View
17
[SID103173718]
IC50 9Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay [AID80057, Type: Literature]
View
18
[SID103173718]
IC50 9Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia [AID94466, Type: Literature]
View
19
[SID103173718]
IC50 9.3Cytotoxicity against rat C6 glioma cell line [AID270650, Type: Literature]
View
20
[SID103173718]
ED50 13.3Mean value for the exposure for P388 to the drug for a period of 60 min [AID152566, Type: Literature]
View
21
[SID103173718]
IC50 15Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytototoxicity Assay [AID145589, Type: Literature]
View
22
[SID103173718]
IC50 15Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay [AID214234, Type: Literature]
View
23
[SID103173718]
IC50 17Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma [AID85435, Type: Literature]
View
24
[SID103173718]
IC50 18Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytototoxicity Assay [AID145731, Type: Literature]
View
25
[SID103173718]
IC50 18Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay [AID9802, Type: Literature]
View
26
[SID103173718]
IC50 20Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay [AID78556, Type: Literature]
View
27
[SID103173718]
IC50 20Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytototoxicity Assay [AID102565, Type: Literature]
View
28
[SID103173718]
IC50 20Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay [AID103238, Type: Literature]
View
29
[SID103173718]
IC50 25Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay [AID208864, Type: Literature]
View
30
[SID103173718]
IC50 27Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytototoxicity Assay [AID202320, Type: Literature]
View
31
[SID103173718]
IC50 37Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytototoxicity Assay [AID57527, Type: Literature]
View
32
[SID48415703]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
33
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Ependymoblastoma (intracerebral) in B6C3F1 mice [AID226, Type: other]
View
34
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lymphosarcoma Mecca (intraperitoneal) in C3AKF1 (CHKRF1) mice [AID304, Type: other]
View
35
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice [AID306, Type: other]
View
36
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia resistant to 6-MP and 6-Thioguanine; NSC 755, NSC 752 (intraperitoneal) in B6D2F1 (BDF1) mice [AID308, Type: other]
View
37
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model C1498 Myeloid Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice [AID312, Type: other]
View
38
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice [AID316, Type: other]
View
39
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P815 Mast Cell Leukemia (Ascitic) (intraperitoneal) in B6D2F1 (BDF1) mice [AID318, Type: other]
View
40
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P329 Reticulum Cell Sarcoma (intraperitoneal) in B6D2F1 (BDF1) mice [AID320, Type: other]
View
41
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 08 (intraperitoneal) in CD2F1 (CDF1) mice [AID322, Type: other]
View
42
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice [AID324, Type: other]
View
43
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to Dihydroxy Anthracenedione; NSC 299195 (intraperitoneal) in CD2F1 (CDF1) mice [AID326, Type: other]
View
44
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice [AID328, Type: other]
View
45
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice [AID330, Type: other]
View
46
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia (intracerebral) in CD2F1 (CDF1) mice [AID334, Type: other]
View
47
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice [AID336, Type: other]
View
48
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P388 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice [AID338, Type: other]
View
49
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Reticulum Cell Sarcoma (Kelley Mouse) (intraperitoneal) in CD2F1 (CDF1) mice [AID340, Type: other]
View
50
[SID479311]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lieberman Plasma Cell No. 1 (LPC-1) (intraperitoneal) in unknown mice [AID344, Type: other]
View